|
 |
| EDITORIAL |
|
|
|
| Year : 2020 | Volume
: 52
| Issue : 1 | Page : 1-5 |
| |
Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach
Phulen Sarma1, Manisha Prajapat1, Pramod Avti2, Hardeep Kaur1, Subodh Kumar1, Bikash Medhi1
1 Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| Date of Submission | 14-Feb-2020 |
| Date of Decision | 15-Feb-2020 |
| Date of Acceptance | 24-Feb-2020 |
| Date of Web Publication | 11-Mar-2020 |
Correspondence Address:
Dr. Bikash Medhi
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijp.IJP_119_20
How to cite this article:
Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol 2020;52:1-5 |
How to cite this URL:
Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol [serial online] 2020 [cited 2023 Sep 29];52:1-5. Available from: https://www.ijp-online.com/text.asp?2020/52/1/1/280269 |
In the 21st century, three coronaviruses (CoVs) caused three major epidemic of respiratory distress[1] syndrome, which include severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 with epicenter in Guangdong, China,[2] Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 in Saudi Arabia,[3] and the third epidemic of respiratory coronavirus the 2019-novel coronavirus (2019-nCoV) or coronavirus disease (COVID-19) mainly centered in Wuhan province, China.[4] The case fatalities vary from 2.5% (2019-nCoV),[5] 10% (SARS), to 35% (MERS-CoV).[6] Till now, there is no approved antiviral or vaccine for the management of infection by CoV. However, from earlier experience of the management of SERS-CoV and MERS-CoV, many agents are being used in the treatment of 2019-nCoV.[7]
| » Antivirals | |  |
Nucleoside analog
Ribavirin, a nucleoside analog, shows antiviral activity against some animal CoVs, and in the SARS-CoV epidemic, many patients were treated with ribavirin along with corticosteroids and became a standard regimen for the treatment of SARS-CoV. However, lack of control group hindered the estimation of true effect size. Again,in vitro testing did not show efficacy of ribavirin against SARS-CoV. Ribavirin is known for its side effects (hemolytic anemia, hypocalcemia, and hypomagnesemia). Many subsequent studies questioned the efficacy of ribavirin. Many patients on ribavirin and corticosteroid combination even showed an increase in viral load following the treatment. Thus, its use declined over a period.[8] Other important nucleoside analogs are favipiravir and galidesivir, but these are not evaluated till now in 2019-nCoV.
Neuraminidase inhibitors
Neuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]
Protease inhibitor
There are two types of protease present in SARS-CoV, the CL-like protease and the papain-like protease, which is important for cleaving the polyproteins and releasing the nonstructural proteins (NSP1–16), which carry out important functions in the CoV life cycle. Among protease inhibitors, lopinavir was the most inhibitor and saquinavir was the least powerful inhibitor of CoV protease.[13] In molecular dynamic studies, flap closing was observed when these inhibitors bound to the SARS-CoV 3CL (pro).[14] Hong Kong University researchers demonstrated anti-SARS-CoV action of lopinavir at concentration of 4 μg/mlin vitro against the HKU-39849 isolate.[15] Ritonavir boosting along with lopinavir is used in the management of HIV.[16] A clinical study at the same Hong Kong University suggests that even after adjustment for LDH level (possible confounder), a significant association was seen between lopinavir/ritonavir use and better outcome.[15] As per the current guidelines, lopinavir + ritonavir is the recommended protease inhibitor for the treatment of 2019-nCoV (weak recommendation).[17]
| » Immunomodulators | | |
Corticosteroids
Corticosteroids were widely used for the treatment of SERS-CoV and MERS-CoV and are also used in the management of the current epidemic of 2019-nCoV. However, the interim guidelines by the WHO prohibit the use of routine corticosteroids unless indicated for other clinical ground.[18] Use of corticosteroid is reported to be associated with delayed clearance of viral RNA (both in case of SERS-CoV and MERS-CoV) and other steroid-related complications such as psychosis.[19]
Interferon
Interferons (IFNs) are broad-spectrum antivirals, primarily used in the treatment of hepatitis B. In SARS-CoV patients, compared to ribavirin or interferon (IFN) alone, the benefit was seen on IFN-α + high-dose corticosteroid group.[20] Other observational studies also support these findings and the combined use of IFN-α and corticosteroid (corticosteroid arm n = 13; corticosteroid + IFN-α arm n = 9) showed less disease-associated oxygen saturation impairment.[21] For the treatment of 2019-nCoV (7), IFN-α (5 million U bid inh) is recommended along with lopinavir + ritonavir combination.[17]
Immunoglobulins
In case of critically ill SARS, who show signs of deterioration, further escalation of immunomodulation is indicated and intravenous (i.v.) immunoglobulin may be considered.[22] Patients who show poor response to initial empirical therapy may get benefit from i.v. immunoglobulin.[23]
| » Host-Directed Therapies | | |
Host-directed therapies basically target improvement of the status of the host, improvement of host immune response, or handling of host-related factors associated with viral replication.[6] Apart from immunomodulators, metformin, atorvastatin, fibrates, as well as nutritional supplements may help in treating acute respiratory distress syndrome (ARDS) by boosting immunity. However, evidence of efficacy in SARS-CoV or MERS-CoV is poorly reported.[24]
Zinc is reported to have antiviral effect,[24] and it inhibits CoV RNA polymerase activity and thus hampers replication in cell culture experiments.[25] As cytokine storm is a pathognomonic feature of COVID-19, inhibition of these pro-inflammatory cytokines may theoretically prove useful (e.g., inhibition of IL-6 by tocilizumab).[24]
| » Other Therapies | | |
Other treatment options, which are either used rarely or in experimental state, are SiRNA, tumor necrosis factor-alpha inhibitors, neutralizing antibodies, pentoxifylline, etc., However, the level of evidence is quite poor and hence not recommended for routine care.[8]
| » Management of 2019-Novel Coronavirus (Coronavirus Disease-19) | | |
Clinical care of suspected patients with 2019-nCoV should focus on recognition of the disease condition at the earliest, isolation and adoption of proper infection control measures, and delivery of optimized supportive care toward the suspected/confirmed cases.[26] For preventive measure, the WHO guideline “Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected” mainly focuses on avoiding close contact with persons suffering from acute respiratory infections, frequent hand wash, and avoidance of unwanted contact with wild animals. In case of patients with respiratory distress, the patient is to be evaluated for the presence of shock. Empirical antimicrobial coverage is to be given (to cover up the likely causative organisms, which may be responsible for severe acute respiratory infection). Special concern is to be given for other comorbid conditions. In case of hypoxemic respiratory failure, it needs to be managed aggressively with high-flow nasal oxygen or noninvasive ventilation or by endotracheal intubation and positive pressure ventilation as required. Special concern is to be taken for the identification and management of septic shock.[27]
| » Treatment of 2019-Novel Coronavirus: Evidence from China | | |
The details of treatment reported in case of 2019-nCoV are presented in [Table 1]. The antiviral agents which are used in the management of 2019-nCoV episodes are lopinavir, ritonavir, arbidol,[28] oseltamivir,[12] i.v. ganciclovir.[29] Among immunomodulators, the commonly used agents are systematic corticosteroids,[12],[30] and i.v. immunoglobulin was used in more serious cases who were refractory to initial therapy.[28] Among herbal medicines, Chinese herbal medicinal products Tanreqing i.v. gtt,[31] shufeng jiedu capsule (a traditional Chinese medicine) was used.[28] The WHO has specified that at this present time there is no high level evidence is available, which favous use of a single specific antiviral agent for the treatment of patients with suspected or confirmed 2019nCoV infection.[27] Although many of the death cases were in higher age group[32] and many were smokers and had bilateral disease,[29] lack of appropriate control group is the main hindrance in interpreting these prognostic factors. | Table 1: Details of reported therapeutic strategies to counter 2019-nCoV infection
Click here to view |
| » Recent Advances in the Treatment of 2019-Novel Coronavirus | | |
Remdesivir and chloroquine[33]
Using clinical isolates of 2019-nCoV, Wang et al., 2020 evaluated the efficacy of seven agents (ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine, remdesivir [GS5734], and favipiravir (T-705)) inin vitro conditions. Cytotoxicity was evaluated in vero E6 cells, which was followed by infection of the cells with 2019-nCoV clinical isolates, and the test drug was evaluated at different doses. Reverse transcription polymerase chain reaction-based quantification was done to get the viral yield, which was later confirmed by immunofluorescence microscopy (nucleocapsid protein visualization). Both chloroquine and remdesivir inhibited virus infection at micromolar level (0.77–1.13 μM) and with high selectivity.[33]
Being an adenosine analog, remdesivir gets incorporated into viral RNA and causes premature chain termination.[34] The importance of chloroquine as an antiviral agent is coming up. Chloroquine even showed efficacy as a potent antiviral against SARS-CoV infection and spread.[35] Pretreatment with chloroquine renders vero E6 cells refractory to SARS CoV infection. Moreover, in the postinfection period, treatment with chloroquine prevents the spread of SARS-CoV infection.[35] Chloroquine increases endosomal pH and thus makes the environment unfavorable for the virus/cell fusion. Chloroquine also affects the glycosylation process of angiotensin-converting enzyme 2 (ACE-2, receptor for binding of viral spike protein, which is essential for interaction with the host).[35] Being nonexpensive and easily available agent, chloroquine may prove as a promising candidate.
Baricitinib
The SARSCoV and the 2019nCoV both enters host cells through ACE2 receptormediated entry, especially through AT2 cells present in lungs.[36] Downstream signaling of this receptor mediates the endocytosis process, and AP2-associated protein kinase 1 (AAK1) plays a major role in this process. Thus, AAK1 represents an important target. Richardson et al., 2020 evaluated 378 ligands, of which 47 were already approved for use in other conditions. Among these ligands, six inhibited AAK1 with high affinity. Considering the side effect profile, they found janus kinase inhibitor baricitinib to be the most important agent. In addition to AAK1, baricitinib also binds to another endocytosis regulator protein (cyclin G-associated kinase). Thus, the authors suggest that baricitinib can be evaluated in thein vitro conditions as well as in the clinical trial settings for 2019-nCoV.[37]
Limitations of current research
Lack of high-quality evidence (especially randomized controlled trails [RCTs]) is the most important limitation of the current CoV research. As most of the CoV strains are genetically different and the outbreaks occur extremely randomly, conducting an RCT is extremely difficult, and we have to rely on observational studies (most of which do not have proper control group), which hamper the estimation of proper treatment effect.
| » References | | |
| 1. | Graham RL, Donaldson EF, Baric RS. A decade after SARS: Strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013;11:836-48.  |
| 2. | |
| 3. | |
| 4. | |
| 5. | Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel coronavirus (2019-nCoV): Estimating the case fatality rate – A word of caution. Swiss Med Wkly 2020;150:w20203. |
| 6. | Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discov 2016;15:327-47. |
| 7. | Li G, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020;19:149-50. |
| 8. | Tai DY. Pharmacologic treatment of SARS: Current knowledge and recommendations. Ann Acad Med Singapore 2007;36:438-43. |
| 9. | Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR Recomm Rep 1999;48:1-9. |
| 10. | Bleibtreu A, Jaureguiberry S, Houhou N, Boutolleau D, Guillot H, Vallois D, et al. Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016. BMC Infect Dis 2018;18:331. |
| 11. | Al-Abdely HM, Midgley CM, Alkhamis AM, Abedi GR, Lu X, Binder AM, et al. Middle East respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia. Emerg Infect Dis 2019;25:753-66. |
| 12. | Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. |
| 13. | Dayer MR, Taleb-Gassabi S, Dayer MS. Lopinavir; a potent drug against coronavirus infection: Insight from molecular docking study. Arch Clin Infect Dis 2017;12:e13823. Available from: http://archcid.com/en/articles/13823.html. [Last accessed on 2020 Feb 12]. |
| 14. | Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL (pro) inhibitors. J Theor Biol 2008;254:861-7. |
| 15. | Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 2004;59:252-6. |
| 16. | Oldfield V, Plosker GL. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs 2006;66:1275-99. |
| 17. | Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7:4. |
| 18. | |
| 19. | Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473-5. |
| 20. | Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003;52:715-20. |
| 21. | Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: A preliminary study. JAMA 2003;290:3222-8. |
| 22. | Lau AC, Yam LY, So LK. Management of critically Ill patients with severe acute respiratory syndrome (SARS). Int J Med Sci 2004;1:1-10. |
| 23. | Tsang K, Zhong NS. SARS: Pharmacotherapy. Respirology 2003; 8 Suppl 1:S25-30. doi: 10.1046/j.1440-1843.2003.00525.x. |
| 24. | Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: Host-directed therapies should be an option. Lancet 2020;395:e35-6. |
| 25. | te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010;6:e1001176. |
| 26. | |
| 27. | |
| 28. | Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment [published online ahead of print, 2020 Feb 9]. Biosci Trends 2020;10.5582/bst.2020.01030. doi:10.5582/bst.2020.01030. |
| 29. | Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13. |
| 30. | |
| 31. | Zhang Z, Li X, Zhang W, Shi ZL, Zheng Z, Wang T. Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: Report of a couple cases. Virol Sin 2020. doi: 10.1007/s12250-020-00203-8. |
| 32. | Kui L, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province [published online ahead of print, 2020 Feb 7]. Chin Med J (Engl) 2020;10.1097/CM9.0000000000000744. doi:10.1097/CM9.0000000000000744. |
| 33. | Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71. doi: 10.1038/s41422-020-0282-0. |
| 34. | Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016;531:381-5. |
| 35. | Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69. |
| 36. | Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells [Internet]. Molecular Biology; 2020. Available from: http://biorxiv.org/lookup/doi/10.1101/2020.01.31.929042. [Last cited on 2020 Mar 04]. |
| 37. | Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020;395:e30-1. |
[Table 1]
| This article has been cited by | | 1 |
Insight into the mechanisms of coronaviruses evading host innate immunity |
|
| Tengteng Yao, ChingChoon Foo, Guopei Zheng, Rui Huang, Qian Li, Jianfeng Shen, Zhaoyang Wang | | Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2023; : 166671 | | [Pubmed] | [DOI] | | | 2 |
The ‘myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19’ is far from reality |
|
| Deba Prasad Dhibar, Navneet Arora, Deepak Chaudhary, Ajay Prakash, Bikash Medhi, Neeraj Singla, Ritin Mohindra, Vikas Suri, Ashish Bhalla, Navneet Sharma, Mini P. Singh, P. V. M. Lakshmi, Kapil Goyal, Arnab Ghosh | | Scientific Reports. 2023; 13(1) | | [Pubmed] | [DOI] | | | 3 |
Development of an efficient reproducible cell-cell transmission assay for rapid quantification of SARS-CoV-2 spike interaction with hACE2 |
|
| George Ssenyange, Maya Kerfoot, Min Zhao, Shelli Farhadian, Sidi Chen, Lei Peng, Ping Ren, Charles S. Dela Cruz, Shaili Gupta, Richard E. Sutton | | Cell Reports Methods. 2022; : 100252 | | [Pubmed] | [DOI] | | | 4 |
Nutritional and bioactive profile of different parts of Carica papaya L. in relation to thrombocytopenia |
|
| Muhammad Nouman, Bushra Niaz, Farhan Saeed, Muhammad Umair Arshad, Faqir M. Anjum | | International Journal of Food Properties. 2022; 25(1): 24 | | [Pubmed] | [DOI] | | | 5 |
COVID-19 and vaccination: myths vs science |
|
| Vivek P. Chavda, Yangmin Chen, Jayant Dave, Zhe-Sheng Chen, Subhash C. Chauhan, Murali M. Yallapu, Vladimir N. Uversky, Rajashri Bezbaruah, Sandip Patel, Vasso Apostolopoulos | | Expert Review of Vaccines. 2022; : 1 | | [Pubmed] | [DOI] | | | 6 |
Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity |
|
| Gandarvakottai Senthilkumar Arumugam, Kannan Damodharan, Mukesh Doble, Sathiah Thennarasu | | Molecular Biomedicine. 2022; 3(1) | | [Pubmed] | [DOI] | | | 7 |
Current Treatments and Therapeutic Options for COVID-19 Patients: A
Systematic Review |
|
| Esmaeil Mehraeen, Zeinab Najafi, Bagher Hayati, Mohammad Javaherian, Sajad Rahimi, Omid Dadras, SeyedAhmad SeyedAlinaghi, Maryam Ghadimi, Jean-Marc Sabatier | | Infectious Disorders - Drug Targets. 2022; 22(1) | | [Pubmed] | [DOI] | | | 8 |
Therapeutic Options for the Treatment of 2019-Novel Coronavirus in
India: A Review |
|
| Pratyay Kumar Pahari, Sonal Vyas, Shahbaz Aman, Uday Singh, Kusheswar Prasad Singh, Rohit Tiwari, Meenakshi Dhanawat | | Coronaviruses. 2022; 3(2) | | [Pubmed] | [DOI] | | | 9 |
In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease |
|
| Piyush Kashyap, Mamta Thakur, Nidhi Singh, Deep Shikha, Shiv Kumar, Poonam Baniwal, Yogender Singh Yadav, Minaxi Sharma, Kandi Sridhar, Baskaran Stephen Inbaraj | | Molecules. 2022; 27(19): 6374 | | [Pubmed] | [DOI] | | | 10 |
A REVIEW ON THE IMPACT OF THE COVID-19 PANDEMIC ON THE HEALTH CARE SECTOR |
|
| PRAJITHA BIJU, PALLAVI K., VAGEESH REVADIGAR, SONAL DSOUZA, MOHAMMED ASIF IQBAL, GULZAR AHMED | | International Journal of Pharmacy and Pharmaceutical Sciences. 2021; : 1 | | [Pubmed] | [DOI] | | | 11 |
An update of coronavirus disease 2019 (COVID-19): an essential brief |
|
| Afshin Zare, Seyyede Fateme Sadati-Seyyed-Mahalle, Amirhossein Mokhtari, Nima Pakdel, Zeinab Hamidi, Sahar Almasi-turk, Neda Baghban, Arezoo Khodamehr, Iraj Nabipour, Mohammad Amin Behzadi, Amin Tamadon | | Modern Medical Laboratory Journal. 2021; 4(1): 19 | | [Pubmed] | [DOI] | | | 12 |
Rapid, reliable, and reproducible cell fusion assay to quantify SARS-Cov-2 spike interaction with hACE2 |
|
| Min Zhao, Pei-Yi Su, Danielle A. Castro, Therese N. Tripler, Yingxia Hu, Matthew Cook, Albert I. Ko, Shelli F. Farhadian, Benjamin Israelow, Charles S. Dela Cruz, Yong Xiong, Richard E. Sutton, Michael S. Diamond | | PLOS Pathogens. 2021; 17(6): e1009683 | | [Pubmed] | [DOI] | | | 13 |
Ethical dimensions in randomized trials and off-label use of investigational drugs for COVID-19 treatment |
|
| Pooja Dhupkar, Seema Mukherjee | | Clinical Ethics. 2021; : 1477750921 | | [Pubmed] | [DOI] | | | 14 |
Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions |
|
| Anil K. Sharma, Varruchi Sharma, Arun Sharma, Suresh Pallikkuth, Anil Kumar Sharma | | Current Medicinal Chemistry. 2021; 28(16): 3173 | | [Pubmed] | [DOI] | | | 15 |
Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19 |
|
| Sekhar Talluri | | Combinatorial Chemistry & High Throughput Screening. 2021; 24(5): 716 | | [Pubmed] | [DOI] | | | 16 |
Diagnosis, prevention, and treatment of coronavirus disease: a review |
|
| Manoj Kumar Sarangi, Sasmita Padhi, Shrivardhan Dheeman, Santosh Kumar Karn, L. D. Patel, Dong Kee Yi, Sitansu Sekhar Nanda | | Expert Review of Anti-infective Therapy. 2021; : 1 | | [Pubmed] | [DOI] | | | 17 |
In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain) |
|
| Phulen Sarma, Nishant Shekhar, Manisha Prajapat, Pramod Avti, Hardeep Kaur, Subodh Kumar, Sanjay Singh, Harish Kumar, Ajay Prakash, Deba Prasad Dhibar, Bikash Medhi | | Journal of Biomolecular Structure and Dynamics. 2021; 39(8): 2724 | | [Pubmed] | [DOI] | | | 18 |
Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings |
|
| Pramod Avti, Arushi Chauhan, Nishant Shekhar, Manisha Prajapat, Phulen Sarma, Hardeep Kaur, Anusuya Bhattacharyya, Subodh Kumar, Ajay Prakash, Saurabh Sharma, Bikash Medhi | | Journal of Biomolecular Structure and Dynamics. 2021; : 1 | | [Pubmed] | [DOI] | | | 19 |
An insight into the simulation directed understanding of the mechanism in SARS CoV-2 N-CTD, dimer integrity, and RNA-binding: Identifying potential antiviral inhibitors |
|
| Arushi Chauhan, Pramod K. Avti, Nishant Shekhar, Manisha Prajapat, Phulen Sarma, Namrata Sangwan, Jitender Singh, Anusuya Bhattacharyya, Subodh Kumar, Hardeep Kaur, Saurabh Sharma, Ajay Prakash, Bikash Medhi | | Journal of Biomolecular Structure and Dynamics. 2021; : 1 | | [Pubmed] | [DOI] | | | 20 |
Repurposing metformin for covid-19 complications in patients with type 2 diabetes and insulin resistance |
|
| Payam Hashemi, Shaghayegh Pezeshki | | Immunopharmacology and Immunotoxicology. 2021; 43(3): 265 | | [Pubmed] | [DOI] | | | 21 |
Current updates on adaptive immune response by B cell and T cell stimulation and therapeutic strategies for novel coronavirus disease 2019 (COVID-19) treatment |
|
| Neeraj Pal, Anil Kumar Mavi, Sundip Kumar, Umesh Kumar, Maya Datt Joshi, Rohit Saluja | | Heliyon. 2021; 7(4): e06894 | | [Pubmed] | [DOI] | | | 22 |
Structural and conformational analysis of SARS CoV 2 N-CTD revealing monomeric and dimeric active sites during the RNA-binding and stabilization: Insights towards potential inhibitors for N-CTD |
|
| Arushi Chauhan, Pramod Avti, Nishant Shekhar, Manisha Prajapat, Phulen Sarma, Anusuya Bhattacharyya, Subodh Kumar, Hardeep Kaur, Ajay Prakash, Bikash Medhi | | Computers in Biology and Medicine. 2021; 134: 104495 | | [Pubmed] | [DOI] | | | 23 |
Yogic Neti-Kriya Using Povidone Iodine: Can it have a Preventive Role Against SARS-CoV-2 Infection Gateway? |
|
| Phulen Sarma, Anusuya Bhattacharyya, Ajay Prakash, Hardeep Kaur, Manisha Prajapat, Mukundam Borah, Subodh Kumar, Seema Bansal, Saurabh Sharma, Gurjeet Kaur, Harish Kumar, Dibya Jyoti Sharma, Karuna Kumar Das, Pramod Avti, Bikash Medhi | | Indian Journal of Otolaryngology and Head & Neck Surgery. 2021; | | [Pubmed] | [DOI] | | | 24 |
Therapeutic approaches to coronavirus infection according to “One Health” concept |
|
| Giacomo Rossi, Livio Galosi, Alessandra Gavazza, Matteo Cerquetella, Sara Mangiaterra | | Research in Veterinary Science. 2021; 136: 81 | | [Pubmed] | [DOI] | | | 25 |
Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review |
|
| Subodh Kumar, Phulen Sarma, Hardeep Kaur, Manisha Prajapat, Anusuya Bhattacharyya, Pramod Avti, Nishant Sehkhar, Harpinder Kaur, Seema Bansal, Saniya Mahendiratta, Vidya M. Mahalmani, Harvinder Singh, Ajay Prakash, Anurag Kuhad, Bikash Medhi | | Tissue and Cell. 2021; 70: 101497 | | [Pubmed] | [DOI] | | | 26 |
nCoV-2019 infection induced neurological outcome and manifestation, linking its historical ancestor SARS-CoV and MERS-CoV: a systematic review and meta-analysis |
|
| Ajay Prakash, Harvinder Singh, Phulen Sarma, Anusuya Bhattacharyya, Deba Prasad Dhibar, Neeraj Balaini, Ritu Shree, Manoj Goyal, Manish Modi, Bikash Medhi | | Scientific Reports. 2021; 11(1) | | [Pubmed] | [DOI] | | | 27 |
SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review |
|
| Jahangir Emrani, Maryam Ahmed, Liesl Jeffers-Francis, John C. Teleha, Nathan Mowa, Robert H. Newman, Misty D. Thomas | | International Journal of Biological Macromolecules. 2021; | | [Pubmed] | [DOI] | | | 28 |
Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2 |
|
| Manisha Prajapat, Nishant Shekhar, Phulen Sarma, Pramod Avti, Sanjay Singh, Hardeep Kaur, Anusuya Bhattacharyya, Subodh Kumar, Saurabh Sharma, Ajay Prakash, Bikash Medhi | | Journal of Molecular Graphics and Modelling. 2020; 101: 107716 | | [Pubmed] | [DOI] | | | 29 |
Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review |
|
| Saniya Mahendiratta, Gitika Batra, Phulen Sarma, Harish Kumar, Seema Bansal, Subodh Kumar, Ajay Prakash, Rakesh Sehgal, Bikash Medhi | | Life Sciences. 2020; 258: 118207 | | [Pubmed] | [DOI] | | | 30 |
Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options |
|
| Boxuan Huang, Rongsong Ling, Yifan Cheng, Jieqi Wen, Yarong Dai, Wenjie Huang, Siyan Zhang, Xifeng Lu, Yifeng Luo, Yi-Zhou Jiang | | Molecular Therapy - Methods & Clinical Development. 2020; 18: 367 | | [Pubmed] | [DOI] | | | 31 |
Coronavirus Disease-2019 (COVID-19): An Updated Review |
|
| Mithun Rudrapal, Shubham J. Khairnar, Laxmikant B. Borse, Anil G. Jadhav | | Drug Research. 2020; 70(09): 389 | | [Pubmed] | [DOI] | | | 32 |
Pharmacological treatments of COVID-19 |
|
| Adeleh Sahebnasagh, Razieh Avan, Fatemeh Saghafi, Mojataba Mojtahedzadeh, Afsaneh Sadremomtaz, Omid Arasteh, Asal Tanzifi, Fatemeh Faramarzi, Reza Negarandeh, Mohammadreza Safdari, Masoud Khataminia, Hassan Rezai Ghaleno, Solomon Habtemariam, Amirhosein Khoshi | | Pharmacological Reports. 2020; 72(6): 1446 | | [Pubmed] | [DOI] | | | 33 |
Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis |
|
| Phulen Sarma, Hardeep Kaur, Harish Kumar, Dhruv Mahendru, Pramod Avti, Anusuya Bhattacharyya, Manisha Prajapat, Nishant Shekhar, Subodh Kumar, Rahul Singh, Ashutosh Singh, Deba Prasad Dhibar, Ajay Prakash, Bikash Medhi | | Journal of Medical Virology. 2020; 92(7): 776 | | [Pubmed] | [DOI] | | | 34 |
Possible prophylactic or preventive role of topical povidone iodine during accidental ocular exposure to 2019-nCoV |
|
| Phulen Sarma, Hardeep Kaur, Bikash Medhi, Anusuya Bhattacharyya | | Graefe's Archive for Clinical and Experimental Ophthalmology. 2020; 258(11): 2563 | | [Pubmed] | [DOI] | | | 35 |
Identification of potential inhibitors of SARS-CoV-2 main protease from Aloe vera compounds: A molecular docking study |
|
| Pius T. Mpiana, Koto-te-Nyiwa Ngbolua, Damien S.T. Tshibangu, Jason T. Kilembe, Benjamin Z. Gbolo, Domaine T. Mwanangombo, Clement L. Inkoto, Emmanuel M. Lengbiye, Clement M. Mbadiko, Aristote Matondo, Gedeon N. Bongo, Dorothée D. Tshilanda | | Chemical Physics Letters. 2020; 754: 137751 | | [Pubmed] | [DOI] | | | 36 |
Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study |
|
| Deba Prasad Dhibar, Navneet Arora, Arpit Kakkar, Neeraj Singla, Ritin Mohindra, Vikas Suri, Ashish Bhalla, Navneet Sharma, Mini P. Singh, Ajay Prakash, Lakshmi PVM, Bikash Medhi | | International Journal of Antimicrobial Agents. 2020; 56(6): 106224 | | [Pubmed] | [DOI] | | | 37 |
COVID-19: Structural predictions of viral success |
|
| Richard A. Stein, Lauren M. Young | | International Journal of Clinical Practice. 2020; 74(10) | | [Pubmed] | [DOI] | | | 38 |
CORONAVIRUS and COVID-19: A Systematic Review and Perspective |
|
| Harshal Ashok Pawar, Anjali Harshal Pawar, Sandip Ashok Pawar, Prashant Ashok Pawar | | Current Drug Therapy. 2020; 15(5): 423 | | [Pubmed] | [DOI] | | | 39 |
COVID-19 pandemic crisis—a complete outline of SARS-CoV-2 |
|
| Sana Saffiruddin Shaikh, Anooja P. Jose, Disha Anil Nerkar, Midhuna Vijaykumar KV, Saquib Khaleel Shaikh | | Future Journal of Pharmaceutical Sciences. 2020; 6(1) | | [Pubmed] | [DOI] | | | 40 |
Management of Children with Disease Caused by New Coronaviral Infection (SARS-CoV-2) |
|
| Yurii S. Alexandrovich, Elena N. Baybarina, Alexander A. Baranov, Elena A. Vishneva, Nadezda N. Zvereva, Dmitry O. Ivanov, Daria S. Kruchko, Ivan V. Konovalov, Tatiana V. Kulichenko, Yuri V. Lobzin, Ludmila N. Mazankova, Leyla S. Namazova-Baranova, Yuriy V. Petrenko, Dmitry V. Prometnoy, Konstantin V. Pshenisov, Alexey Yu. Rtishchev, Mukhammad A. Sayfullin, Liliya R. Selimzyanova, Aleksandr N. Uskov, Marina V. Fedoseenko, Andrey V. Khar’kin, Olga V. Chumakova, Kamilla E. Efendieva, Alexey V. Yakovlev | | Pediatric pharmacology. 2020; 17(2): 103 | | [Pubmed] | [DOI] | | | 41 |
Clinical Features and Management of the Disease Caused by New Coronaviral Infection (COVID-19) in Children. Version 2 |
|
| Yurii S. Alexandrovich, Ekaterina I. Alekseeva, Maya D. Bakradze, Alexander A. Baranov, Tatiana T. Batysheva, Nato D. Vashakmadze, Marina G. Vershinina, Elena A. Vishneva, Anastasia A. Glazyrina, Olga B. Gordeeva, Elena Yu. Dyakonova, ?lena S. Zholobova, Dmitry V. Zabolotsky, Nadezda N. Zvereva, Irina V. Zelenkova, Dmitry O. Ivanov, Elena V. Kaytukova, George A. Karkashadze, Ivan V. Konovalov, Daria S. Kruchko, Tatiana V. Kulichenko, Seda Kh. Kurbanova, Yliya G. Levina, Yuri V. Lobzin, Ludmila N. Mazankova, Tea V. Margieva, Leyla S. Namazova-Baranova, Yulia Yu. Novikova, Dmitry Yu. Ovsyannikov, Elena E. Petryaykina, Yuriy V. Petrenko, Nataliya V. Petrova, Dmitry V. Prometnoy, Konstantin V. Pshenisov, Gregory V. Revunenkov, Alexey Yu. Rtishchev, Dina S. Rusinova, Mukhammad A. Sayfullin, Ruslan F. Sayfullin, Liliya R. Selimzyanova, Vladimir K. Tatochenko, Rustem F. Tepaev, Aleksandr N. Uskov, Marina V. Fedoseenko, Andrey P. Fisenko, Andrey V. Khar’kin, Kamilla E. Efendieva, Alexey V. Yak | | Pediatric pharmacology. 2020; 17(3): 187 | | [Pubmed] | [DOI] | | | 42 |
Povidone Iodine (PVP-I) mouth gargle/nasal spray may be the simplest and cost effective therapeutic antidote for COVID-19 Frontier |
|
| Khalil Ibrahim | | Archives of Community Medicine and Public Health. 2020; : 138 | | [Pubmed] | [DOI] | | | 43 |
Increasing Age, the Existence of Comorbidities, and Corticosteroid Treatment in Combination With Antiviral Therapy Prolongs the Recovery of SARS-COV-2-Infected Patients, Measured as the Conversion From Positive to Negative rtPCR: A 239 Patients' Retrospec |
|
| Sheng Zhu, Yaxiong Huang, Wei Tang, Andreas K. Nussler, Fang Zheng | | Frontiers in Medicine. 2020; 7 | | [Pubmed] | [DOI] | | | 44 |
Fighting Strategies Against the Novel Coronavirus Pandemic: Impact on Global Economy |
|
| Bapi Gorain, Hira Choudhury, Nagashekhara Molugulu, Rajani B. Athawale, Prashant Kesharwani | | Frontiers in Public Health. 2020; 8 | | [Pubmed] | [DOI] | | | 45 |
Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 |
|
| Jiansheng Huang, Wenliang Song, Hui Huang, Quancai Sun | | Journal of Clinical Medicine. 2020; 9(4): 1131 | | [Pubmed] | [DOI] | | | 46 |
Final Countdown to the COVID-19 Lockdown!!
|
|
| Prasoon Kumar, Ashish Behera | | Journal of Postgraduate Medicine, Education and Research. 2020; 54(2): 27 | | [Pubmed] | [DOI] | | | 47 |
An Overview of COVID-19: Focus on Pharmacological Aspect
|
|
| Nandhini Saravanabavan, Padmavathi Shanmuganathan, Manimekalai Kumarappan, Kartik J Salwe, Barathane Datchanamurthy, Johan Pandian, R Sudar Codi, Vimala Ananthy, Kamalasundar Thanuskodi, Uma Narayanamurthy | | SBV Journal of Basic, Clinical and Applied Health Science. 2020; 3(2): 75 | | [Pubmed] | [DOI] | |
|
|
|
|
|
|
|
|
